Orthros TR BV

It is Orthros TR B.V.’s ambition to introduce into the market the first of its kind disease modifying osteoarthritic drugs (DMOADs) for the management of OsteoArthritis (OA), a common and as of yet incurable disease with a prevalence of 10-15% of people world-wide. Orthros TR’s DMOADs consist of small recombinantly produced antibody fragments (VHHs) and belong to the class of biologicals. Orthros TR has presently an unique set of 20 building blocks (VHHs) but this number is rapidly expanding to develop effective antibody based therapeutics. The treatment is patented, minimally invasive, long lasting and has minimal side effects.

The market perspectives are huge; The vast majority of the 120.000.000 OA patients worldwide is not adequately treated. Orthros TR will grow from €40K in revenues in 2018 to a projected revenue of € 11.4 million in 2025 (micro-dosing trials). The growth after 2025 can be exponential due to EMA/ FDA-approval with expecting revenues exceeding € 50 million in 2028.

Orthros TR is led by two scientific experts in the field, Prof. Dr. Theo Verrips and Prof. Dr. Marcel Karperien. The team is complemented by Lucas Oosterhof MSc., an experienced business developer with a proven track record in marketing and sales. In 2018 Orthros TR will start
characterization and production of its unique products and will carry out its first GLP and GMP production for which it has already an order. There is a capital/ financing need of k€ 700 in combination with a € 700k lease to buy equipment for GLP and GMP production to develop Orthros TR into a profitable enterprise within 5 years.

  • Projectnummer / Project number: 17035
  • Projectleider / Project leader: prof. dr. ir. C.T. Verrips - Orthros TR B.V.
  • Type project / Type project: Lopend
  • Startdatum / Start date: 1-09-2018
  • Programma / Programme: Take-off
  • Vakgebied / Discipline: Geneeskunde